Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Analytical Biochemistry|November 24, 2011
High-performance liquid chromatography-tandem mass spectrometry assay of fatty acid amide hydrolase (FAAH) in blood: FAAH inhibition as clinical biomarkerUdeni Yapa, Jeffery J Prusakiewicz, Ann D Wrightstone, et al.
Analytical Chemistry|September 26, 2007
Flexible automated approach for quantitative liquid handling of complex biological samplesJoe Palandra, David Weller, Gary Hudson, et al.
Regulatory Toxicology and Pharmacology : RTP|November 12, 2009
Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injuryJosef S Ozer, Raj Chetty, Gerry Kenna, et al.
Biomarkers in Medicine|June 17, 2010
Recommendations to qualify biomarker candidates of drug-induced liver injuryJosef S Ozer, Raj Chetty, Gerry Kenna, et al.
Frontiers in Bioinformatics|October 28, 2022
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody ProgramsGeorgi I Kapitanov, Jeffrey R Chabot, Jatin Narula, et al.
Gene Therapy|November 5, 2021
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophyVahid Farrokhi, Jason Walsh, Joe Palandra, et al.
Molecular Pharmacology|April 17, 2008
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampinHani Zaher, Henriette E Meyer zu Schwabedissen, Rommel G Tirona, et al.
Journal of Neurology|January 12, 2017
Reduced serum myostatin concentrations associated with genetic muscle disease progressionPeter M Burch, Oksana Pogoryelova, Joe Palandra, et al.
Therapeutic Advances in Gastroenterology|February 13, 2026
Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trialStefan Schreiber, Silvio Danese, Séverine Vermeire, et al.
Pharmacogenetics and Genomics|April 15, 2008
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probeBradley L Urquhart, Joseph A Ware, Rommel G Tirona, et al.
Pageof 4